These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 34132050)
1. In vitro dissolution considerations associated with nano drug delivery systems. Gupta R; Chen Y; Xie H Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Nov; 13(6):e1732. PubMed ID: 34132050 [TBL] [Abstract][Full Text] [Related]
2. In vitro - in vivo correlation: from theory to applications. Emami J J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187 [TBL] [Abstract][Full Text] [Related]
3. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. Uppoor VR J Control Release; 2001 May; 72(1-3):127-32. PubMed ID: 11389991 [TBL] [Abstract][Full Text] [Related]
4. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation. Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538 [TBL] [Abstract][Full Text] [Related]
5. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model. Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663 [TBL] [Abstract][Full Text] [Related]
6. Towards in vitro - In vivo correlation models for in situ forming drug implants. Wang X; Roy M; Wang R; Kwok O; Wang Y; Wang Y; Qin B; Burgess DJ J Control Release; 2024 Aug; 372():648-660. PubMed ID: 38936743 [TBL] [Abstract][Full Text] [Related]
7. Conventional vs Mechanistic IVIVC: A Comparative Study in Establishing Dissolution Safe Space for Extended Release Formulations. Kollipara S; Ahmed T; Chougule M; Guntupalli C; Sivadasu P AAPS PharmSciTech; 2024 May; 25(5):118. PubMed ID: 38806735 [TBL] [Abstract][Full Text] [Related]
8. In-vitro in-vivo correlation (IVIVC) in nanomedicine: Is protein corona the missing link? Jain P; Pawar RS; Pandey RS; Madan J; Pawar S; Lakshmi PK; Sudheesh MS Biotechnol Adv; 2017 Nov; 35(7):889-904. PubMed ID: 28844973 [TBL] [Abstract][Full Text] [Related]
9. Regulatory Experience with In Vivo In Vitro Correlations (IVIVC) in New Drug Applications. Suarez-Sharp S; Li M; Duan J; Shah H; Seo P AAPS J; 2016 Nov; 18(6):1379-1390. PubMed ID: 27480319 [TBL] [Abstract][Full Text] [Related]
10. Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report. Suarez-Sharp S; Cohen M; Kesisoglou F; Abend A; Marroum P; Delvadia P; Kotzagiorgis E; Li M; Nordmark A; Bandi N; Sjögren E; Babiskin A; Heimbach T; Kijima S; Mandula H; Raines K; Seo P; Zhang X AAPS J; 2018 Aug; 20(6):93. PubMed ID: 30151612 [TBL] [Abstract][Full Text] [Related]
11. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen. Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158 [TBL] [Abstract][Full Text] [Related]
12. Self Nanoelmusifying Drug Delivery System of Rosuvastatin: Bioavailability Evaluation and Phan NT; Tran YTH; Nguyen LT; Hoang YK; Bui CK; Nguyen HD; Vu GTT Curr Drug Deliv; 2024; 21(5):734-743. PubMed ID: 36545742 [TBL] [Abstract][Full Text] [Related]
13. Injectable drug delivery systems of doxorubicin revisited: In vitro-in vivo relationships using human clinical data. Modh H; Fang DJ; Ou YH; Yau JNN; Kovshova T; Nagpal S; Knoll J; Wallenwein CM; Maiti K; Bhowmick S; Gelperina S; Pastorin G; Wacker MG Int J Pharm; 2021 Oct; 608():121073. PubMed ID: 34481887 [TBL] [Abstract][Full Text] [Related]
14. Developing a robust in vitro release method for a polymeric nanoparticle: Challenges and learnings. Mead H; Paraskevopoulou V; Smith N; Gibson R; Amerio-Cox M; Taylor-Vine G; Armstrong T; Harris K; Wren S; Mann J Int J Pharm; 2023 Sep; 644():123317. PubMed ID: 37586575 [TBL] [Abstract][Full Text] [Related]
15. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead. Hock SC; Ying YM; Wah CL PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077 [TBL] [Abstract][Full Text] [Related]
16. Nanomedicine at the crossroads - A quick guide for IVIVC. Mast MP; Modh H; Champanhac C; Wang JW; Storm G; Krämer J; Mailänder V; Pastorin G; Wacker MG Adv Drug Deliv Rev; 2021 Dec; 179():113829. PubMed ID: 34174332 [TBL] [Abstract][Full Text] [Related]
17. Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system. Tian C; Zheng S; Liu X; Kamei KI J Nanobiotechnology; 2022 Jul; 20(1):338. PubMed ID: 35858898 [TBL] [Abstract][Full Text] [Related]
18. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development. Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761 [TBL] [Abstract][Full Text] [Related]
19. PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective. Stillhart C; Pepin X; Tistaert C; Good D; Van Den Bergh A; Parrott N; Kesisoglou F AAPS J; 2019 Jan; 21(2):19. PubMed ID: 30673891 [TBL] [Abstract][Full Text] [Related]
20. In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC. Ruiz Picazo A; Martinez-Martinez MT; Colón-Useche S; Iriarte R; Sánchez-Dengra B; González-Álvarez M; García-Arieta A; González-Álvarez I; Bermejo M Mol Pharm; 2018 Jun; 15(6):2307-2315. PubMed ID: 29746133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]